MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes

inCompany News

Metabolon to perform metabolomic analysis for Lactation Lab.

MORRISVILLE, N.C. – December 13, 2021 – Metabolon, Inc., will collaborate with Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center (BIDMC) in a first-of-its-kind Lactation Lab, providing comprehensive metabolomic profiles to enhance understanding of the biology underlying lactation to identify solutions to improve maternal and infant health.

The value of this work is two-fold. In the short-term, the findings will generate fundamental knowledge required for the discovery of interventions to improve maternal and infant health outcomes. In the long-term, the development of the Lactation Lab will provide a model for discovery in the field of lactation science, bringing much-needed scientific rigor to investigations during this critical period that influences the lifelong health of two generations.

“We are thrilled to collaborate with Drs. Sarbattama Sen and Camilia Martin to support the multidisciplinary research work at The Lactation Lab,” says Patricia Sheridan, Ph.D., Associate Director, Biological Development, Metabolon. “Metabolon’s data will enable the identification of the metabolomic signatures of mothers and infants following birth and through the breastfeeding period, providing data to identify key biochemicals that may be crucial for improving the health of both the mother and baby.”

“Over 60 percent of U.S. women are unable to achieve their lactation goals, and the variability in human breastmilk has been understudied,” said Sarbattama Sen, MD, a physician in the Department of Pediatric Newborn Medicine at Brigham and Women’s Hospital. “Leveraging techniques such as metabolomics will be critical to moving forward the field of lactation science and optimizing care for every mother and infant.”

Research has shown that longer breastfeeding duration can decrease post-partum weight retention and metabolic issues, while also decreasing the possibility post-partum depression and rates of breast and ovarian cancer.

“Detailed characterization of human milk coupled with clinical outcomes will identify important pathways in health and disease for both mother and infant,” adds Dr. Camilia Martin, Director of Clinical-Translational Research in the Department of Neonatology at Beth Israel Deaconess Medical Center. “These findings will catalyze new areas of research on previously unrecognized metabolites that are important for health outcomes.

Metabolon’s collaboration with Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center is part of 11 independent projects that are receiving funding from Massachusetts Life Sciences Center. The MLSC is contributing $8.3 million in capital programs to support innovation and cross-sector collaboration to tackle pressing life science challenges in women’s health.

​Metabolon will perform global metabolomics on breast milk and plasma samples from mothers and plasma samples from their babies. These studies represent geographically and demographically diverse cohorts and a unique opportunity to utilize Metabolon’s platform to improve maternal and child health.

About Metabolomics

Metabolomics, the large-scale study of all small molecules in a biological system, is the only ‘omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond just the genetic variation of individuals by capturing the combined impact of genetic as well as external factors, such as the effect of drugs, diet, lifestyle and the microbiome on human health.​ By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers that can enable understanding of a drug’s mechanism of action (MOA), pharmacodynamics, safety profile, and individual response to therapy. ​

About Metabolon 
Metabolon, Inc., is the global leader in metabolomics, with a mission to deliver metabolomics data and insights that expand and accelerate the impact of life sciences research in all its applications. Over 20 years, 10,000+ projects, 2,000+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific technology and bioinformatics techniques. Our Precision Metabolomics™ Platform has enabled the development of the world’s largest proprietary metabolomics reference library. Our industry-leading data and translational science experts help our clients address some of the most challenging and pressing questions in the life sciences, accelerating research, and development success. The company offers scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com and follow us on LinkedIn and Twitter.

Media Inquiries:

Elizabeth Romero, Manager, Marketing Communications, Metabolon, Inc., Mobile: 984-243-1413, [email protected] 

Back to News & Events
  • Bile acid quantification provides insight into the mechanism of action for the treatment of NASH
    Previous PostBile acid quantification provides insight into the mechanism of action for the treatment of NASH
  • Next PostOvercoming the Limitations of Mass Spectrometry Across Datasets
    Bile acid quantification provides insight into the mechanism of action for the treatment of NASH

Related Posts

Event: Precision Medicine World Conference (PMWC)
Events

Event: Precision Medicine World Conference (PMWC)

Metabolon Appoints New Vice President of Global Marketing, Supporting Commercial Product Expansion
Company News

Metabolon Appoints New Vice President of Global Marketing, Supporting Commercial Product Expansion

Webinar: Integrated Multiomic Analysis for Disease
Events

Webinar: Integrated Multiomic Analysis for Disease

Metabolomics in drug discovery: The missing piece for multi-omics data
Events

Metabolomics in drug discovery: The missing piece for multi-omics data

How Metabolomics Can Raise the Bar in Drug Development
Drug Development Working with Metabolon

How Metabolomics Can Raise the Bar in Drug Development

Metabolon Announces Chief Financial Officer Transition
Company News

Metabolon Announces Chief Financial Officer Transition

Lunch and Learn: Applications of Metabolomics in Microbiome Research
Events

Lunch and Learn: Applications of Metabolomics in Microbiome Research

Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen
Company News

Metabolon to Power Metabolomic Enriched Population Health Studies at FinnGen

Overcoming the Limitations of Mass Spectrometry Across Datasets
Blog Capabilities Working with Metabolon

Overcoming the Limitations of Mass Spectrometry Across Datasets

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes
Company News

Leading medical centers leverage metabolomics to better understand the impact of lactation on birth and maternal outcomes

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in
Copy